Oliver Glass, Ricardo Henao, Keyur Patel, Cynthia D. Guy, Hans J. Gruss, Wing‐Kin Syn, Cynthia A. Moylan, Robert Streilein, Russell Hall, Anna Mae Diehl, Manal F. Abdelmalek – 21 September 2018 – The severity of hepatic fibrosis is the primary predictor of liver‐related morbidity and mortality in patients with nonalcoholic fatty liver disease (NAFLD). Unfortunately, noninvasive serum biomarkers for NAFLD‐associated fibrosis are limited. We analyzed baseline serum samples for 24 cytokines of 97 patients with biopsy‐proven NAFLD.

Aya Ugamura, Po‐sung Chu, Nobuhiro Nakamoto, Nobuhito Taniki, Keisuke Ojiro, Taizo Hibi, Masahiro Shinoda, Hideaki Obara, Yohei Masugi, Akihiro Yamaguchi, Shunsuke Shiba, Rei Morikawa, Shingo Usui, Hirotoshi Ebinuma, Yuko Kitagawa, Hidetsugu Saito, Takanori Kanai – 21 September 2018 – A prognostic system for acute liver failure (ALF) with a higher predictive value is urgently needed. The role of extracellular matrix (ECM) remodeling in ALF has not been fully elucidated.

Virginia Hernández‐Gea, Juan Carlos Garcia‐Pagan – 21 September 2018

Patrick H. Y. Chung, Kelvin K. C. Ng, Tiffany C. L. Wong, Sui Ling Sin, Chung Mau Lo – 21 September 2018

Janghyun Kim, Bora Lee, Dae‐Hwan Kim, Jae Gwang Yeon, Jeongkyung Lee, Younjung Park, Yuna Lee, Soo‐Kyung Lee, Seunghee Lee, Jae W. Lee – 19 September 2018 – Regulation of the protein stability of epigenetic regulators remains ill‐defined despite its potential applicability in epigenetic therapies. The histone H3‐lysine 4‐methyltransferase MLL4 is an epigenetic transcriptional coactivator that directs overnutrition‐induced obesity and fatty liver formation, and Mll4+/‐ mice are resistant to both.

Charlotte E. Costentin, Yanik J. Bababekov, Andrew X. Zhu, Heidi Yeh – 19 September 2018 – Liver transplantation (LT) is considered the optimal treatment for hepatocellular carcinoma (HCC) because it removes tumor as well as the underlying cirrhotic liver. Because of a global organ shortage, LT for patients with HCC is limited to patients with expected survival comparable to that of nonmalignant indications. Therefore, identifying patients with lower rates of HCC recurrence and higher rates of survival is critical.

Charlotte E. Costentin, Yanik J. Bababekov, Andrew X. Zhu, Heidi Yeh – 19 September 2018 – Liver transplantation (LT) is considered the optimal treatment for hepatocellular carcinoma (HCC) because it removes tumor as well as the underlying cirrhotic liver. Because of a global organ shortage, LT for patients with HCC is limited to patients with expected survival comparable to that of nonmalignant indications. Therefore, identifying patients with lower rates of HCC recurrence and higher rates of survival is critical.

Olympia E. Anastasiou, Marek Widera, Sandra Westhaus, Lejla Timmer, Johannes Korth, Guido Gerken, Ali Canbay, Daniel Todt, Eike Steinmann, Tatjana Schwarz, Jörg Timm, Jens Verheyen, Sandra Ciesek – 19 September 2018 – Acute hepatitis B virus (HBV) infection remains a frequent cause of acute liver failure (ALF) worldwide. ALF occurs in 0.1%‐0.5% of infected patients. The aim of this study was to scrutinize the outcome of patients with HBV‐induced ALF and mutational patterns of HBV variants, which might contribute to ALF.

Takeo Toshima, Tomoharu Yoshizumi, Masahiro Shimokawa, Toru Ikegami, Noboru Harada, Shinji Itoh, Yohei Mano, Takashi Motomura, Yuji Soejima, Yoshihiko Maehara – 19 September 2018

Jeannette D. Widmer, Andrea Schlegel, Mohamed Ghazaly, Brian Richie Davidson, Charles Imber, Dinesh Sharma, Massimo Malago, Joerg‐Matthias Pollok – 19 September 2018 – The cava‐preserving piggyback (PB) technique requires only partial cava clamping during the anhepatic phase in liver transplantation (LT) and, therefore, maintains venous return and may hemodynamically stabilize the recipient. Hence, it is an ongoing debate whether PB implantation is more protective from acute kidney injury (AKI) after LT when compared with a classic cava replacement (CR) technique.